- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 253/065 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 253/065
Total number of patents in this class: 42
10-year publication summary
|
5
|
5
|
0
|
5
|
2
|
5
|
2
|
1
|
3
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| HMI Medical Innovations, LLC | 14 |
8 |
| Green Cross Corporation | 219 |
2 |
| Guangdong Aglaia Optoelectronic Materials Co., Ltd. | 179 |
2 |
| Health Research, Inc. | 340 |
2 |
| Legochem Biosciences, Inc. | 50 |
2 |
| Pierre Fabre Dermo-Cosmetique | 361 |
2 |
| Receptos LLC | 61 |
2 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 876 |
2 |
| Mineralys Therapeutics, Inc. | 30 |
2 |
| Bristol-myers Squibb Company | 4764 |
1 |
| BASF SE | 21320 |
1 |
| LG Chem, Ltd. | 17956 |
1 |
| Merck Sharp & Dohme Corp. | 2184 |
1 |
| The Regents of the University of Michigan | 5023 |
1 |
| The Johns Hopkins University | 5922 |
1 |
| National Taiwan University | 1328 |
1 |
| Institute for OneWorld Health | 16 |
1 |
| Kadmon Corporation, LLC | 108 |
1 |
| Legochem Bioscience Ltd. | 16 |
1 |
| Magenta Therapeutics, Inc. | 47 |
1 |
| Other owners | 7 |